Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

OLATOYOSI M ODENIKE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1194887646
CMS profile
99079
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$4,975.41

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,390.00 1
Travel and Lodging $1,090.90 5
Food and Beverage $494.51 7

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Celgene Corporation $3,516.65 3
AbbVie, Inc. $1,209.53 7
Novartis Pharmaceuticals Corporation $135.00 1
Taiho Oncology, Inc. $100.84 1
JAZZ PHARMACEUTICALS INC. $13.39 1

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

OLATOYOSI M ODENIKE

NPI 1194887646 · CMS profile ID 99079

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194887646?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
OLATOYOSI M ODENIKE, NPI 1194887646, CMS profile ID 99079. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194887646?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). OLATOYOSI M ODENIKE, NPI 1194887646, CMS profile ID 99079. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194887646?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
OLATOYOSI M ODENIKE, NPI 1194887646, CMS profile ID 99079, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1194887646?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $4,975.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Taiho Oncology, Inc. $100.8412/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679425331 CMS
AbbVie, Inc. $239.9610/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647893785 CMS
AbbVie, Inc. $43.0010/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647893787 CMS
AbbVie, Inc. $28.4710/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647893789 CMS
AbbVie, Inc. $170.0010/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647893791 CMS
AbbVie, Inc. $64.2310/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647893797 CMS
AbbVie, Inc. $214.0010/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647893793 CMS
AbbVie, Inc. $449.8710/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647893795 CMS
Novartis Pharmaceuticals Corporation $135.0006/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659894551 CMS
Celgene Corporation $3,390.0005/21/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673018151 CMS
Celgene Corporation $109.5805/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672861393 CMS
Celgene Corporation $17.0705/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672863499 CMS
JAZZ PHARMACEUTICALS INC. $13.3904/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684178899 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,975.41 13
PY2020 $8,990.00 3
PY2021 $11,923.60 10
PY2023 $16,954.12 16
PY2024 $3,862.50 4
PY2025 $4,631.25 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $136,498.65 16
PY2024 Recipient $579.84 2
PY2024 Principal investigator $57,505.53 9
PY2023 Principal investigator $540,389.47 36
PY2022 Principal investigator $455,007.19 49
PY2021 Principal investigator $651,058.16 62
PY2020 Recipient $3,300.00 1
PY2020 Principal investigator $749,494.38 87
PY2019 Principal investigator $687,194.48 104

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $9,620.00 12/28/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A SINGLE-ARM, OPEN-LABEL PHARMACOKINETIC, SAFETY, AND EFFICACY STUDY OF ASTX727 IN COMBINATION WITH VENETOCLAX IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA No dispute reported 06/30/2026 1061058143
Principal investigator 1 ABBVIE INC. $3,441.25 12/13/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 998411731
Principal investigator 1 ABBVIE INC. $500.00 12/13/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 998411733
Principal investigator 1 ABBVIE INC. $206.25 12/07/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 998411317
Principal investigator 1 ABBVIE INC. $125.00 11/09/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 998407885
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $5,000.00 11/08/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A RANDOMIZED, OPEN-LABEL, PHASE 1-2 STUDY OF ASTX727 LOW DOSE (ASTX727 LD) EXTENDED SCHEDULE IN SUBJECTS WITH LOWER RISK (IPSS LOW OR INTERMEDIATE-1) MYELODYSPLASTIC SYNDROMES (MDS) No dispute reported 06/30/2026 1061058139
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $3,177.61 11/08/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A SINGLE-ARM, OPEN-LABEL PHARMACOKINETIC, SAFETY, AND EFFICACY STUDY OF ASTX727 IN COMBINATION WITH VENETOCLAX IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA No dispute reported 06/30/2026 1061058141
Principal investigator 1 ABBVIE INC. $1,165.63 10/12/2023 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 998403693
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $113,707.93 09/23/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A SINGLE-ARM, OPEN-LABEL PHARMACOKINETIC, SAFETY, AND EFFICACY STUDY OF ASTX727 IN COMBINATION WITH VENETOCLAX IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA No dispute reported 06/30/2026 1061058137
Principal investigator 1 ABBVIE INC. $1,056.25 09/13/2023 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 998399319
Principal investigator 1 ABBVIE INC. $61,069.96 08/02/2023 Non-covered Recipient Entity
THE UNIVERSITY OFCHICAGO
Phase I dose study of venetoclax in combination with decitabine 10-day regimen in subjects with high-risk acute myeloid leukemia (AML) No dispute reported 06/30/2026 998393207
Principal investigator 1 ABBVIE INC. $19,851.25 07/20/2023 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
Phase I dose study of venetoclax in combination with decitabine 10-day regimen in subjects with high-risk acute myeloid leukemia (AML) No dispute reported 06/30/2026 998392033
Principal investigator 1 ABBVIE INC. $1,165.63 07/13/2023 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 998391341
Principal investigator 1 ABBVIE INC. $2,442.24 07/10/2023 Non-covered Recipient Entity
THE UNIVERSITY OFCHICAGO
Phase I dose study of venetoclax in combination with decitabine 10-day regimen in subjects with high-risk acute myeloid leukemia (AML) No dispute reported 06/30/2026 998390077
Principal investigator 1 ABBVIE INC. $3,053.28 07/10/2023 Non-covered Recipient Entity
THE UNIVERSITY OFCHICAGO
Phase I dose study of venetoclax in combination with decitabine 10-day regimen in subjects with high-risk acute myeloid leukemia (AML) No dispute reported 06/30/2026 998390079
Principal investigator 1 ABBVIE INC. $30,534.98 07/10/2023 Non-covered Recipient Entity
THE UNIVERSITY OFCHICAGO
Phase I dose study of venetoclax in combination with decitabine 10-day regimen in subjects with high-risk acute myeloid leukemia (AML) No dispute reported 06/30/2026 998390081
Principal investigator 1 ABBVIE INC. $814.08 07/06/2023 Non-covered Recipient Entity
THE UNIVERSITY OFCHICAGO
Phase I dose study of venetoclax in combination with decitabine 10-day regimen in subjects with high-risk acute myeloid leukemia (AML) No dispute reported 06/30/2026 998389963
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $184,213.81 07/01/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A SINGLE-ARM, OPEN-LABEL PHARMACOKINETIC, SAFETY, AND EFFICACY STUDY OF ASTX727 IN COMBINATION WITH VENETOCLAX IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA No dispute reported 06/30/2026 1061058135
Principal investigator 1 ABBVIE INC. $1,056.25 06/15/2023 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 998387057
Principal investigator 1 ABBVIE INC. $500.00 05/24/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 998384339
Principal investigator 1 ABBVIE INC. $1,000.00 05/24/2023 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 998384341
Principal investigator 1 ABBVIE INC. $1,356.25 05/16/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 998383499
Principal investigator 1 ABBVIE INC. $1,056.25 05/16/2023 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 998383507
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $500.00 05/11/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A RANDOMIZED, OPEN-LABEL, PHASE 1-2 STUDY OF ASTX727 LOW DOSE (ASTX727 LD) EXTENDED SCHEDULE IN SUBJECTS WITH LOWER RISK (IPSS LOW OR INTERMEDIATE-1) MYELODYSPLASTIC SYNDROMES (MDS) No dispute reported 06/30/2026 1061058131
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $3,180.08 05/11/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A SINGLE-ARM, OPEN-LABEL PHARMACOKINETIC, SAFETY, AND EFFICACY STUDY OF ASTX727 IN COMBINATION WITH VENETOCLAX IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA No dispute reported 06/30/2026 1061058133
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $7,800.00 05/04/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A SINGLE-ARM, OPEN-LABEL PHARMACOKINETIC, SAFETY, AND EFFICACY STUDY OF ASTX727 IN COMBINATION WITH VENETOCLAX IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA No dispute reported 06/30/2026 1061058129
Principal investigator 1 ABBVIE INC. $1,165.63 04/12/2023 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 998377807
Principal investigator 1 ABBVIE INC. $36,742.00 03/30/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome No dispute reported 06/30/2026 998375967
Principal investigator 1 ABBVIE INC. $1,337.50 03/22/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 998375383
Principal investigator 1 ABBVIE INC. $1,972.48 03/13/2023 Non-covered Recipient Entity
THE UNIVERSITY OFCHICAGO
Phase I dose study of venetoclax in combination with decitabine 10-day regimen in subjects with high-risk acute myeloid leukemia (AML) No dispute reported 06/30/2026 998373739
Principal investigator 1 ABBVIE INC. $1,165.63 02/15/2023 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 998370725
Principal investigator 1 Celgene Corporation $3,744.00 02/10/2023 Non-covered Recipient Entity
The University Of Chicago Kovler Diabetes Center
Phase IIA AG-221-AML-005 - A Phase 1b/2 open-label, randomized study of 2 combinations of Isocitrate dehydrogenase (IDH) mutant targeted therapies plus Azacitidine: oral AG-120 plus subcutaneous Azacitidine and oral AG-221 plus SC Azacitidine in subjects No dispute reported 06/30/2026 1026489347
Principal investigator 1 Eli Lilly and Company $27,612.00 01/18/2023 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A PHASE 1 STUDY OF ORAL LY3410738 IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES WITH IDH1 OR IDH2 MUTATIONS No dispute reported 06/30/2026 1038152045
Principal investigator 1 ABBVIE INC. $1,500.00 01/12/2023 Non-covered Recipient Entity
THE UNIVERSITY OF CHICAGO
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis No dispute reported 06/30/2026 998366587
Principal investigator 1 ABBVIE INC. $1,056.25 01/12/2023 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 998366589
Principal investigator 1 ABBVIE INC. $6,500.00 01/12/2023 Non-covered Recipient Entity
UNIVERSITY OF CHICAGO
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naive Higher-Risk Myelodysplastic Syndromes (MDS) No dispute reported 06/30/2026 998366591